Yumanity Therapeutics’ YTX-7739 Achieved Target Engagement at Doses That Were Generally Well Tolerated in a Phase 1a Multiple Ascending Dose Study in Healthy Volunteers
YTX-7739 is Yumanity’s lead product candidate in clinical development for the treatment of Parkinson’s diseaseBOSTON, April 22, 2021 (GLOBE NEWSWIRE)...